| DC74693 |
WAY-301464 |
WAY-301464 is a Pim-1 inhibitor. |
|
| DC74694 |
BIT225 |
BIT-225 is a NCp7 zinc finger inhibitor potentially for the treatment of HCV infection and HIV infection. BIT225 inhibits HIV-1 replication in myeloid dendritic cells. BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues. BIT225 against HIV-1 release from human macrophages. |
|
| DC74695 |
AFN-1252 |
AFN-1252, also known as AFN-12520000; API-1252; Debio-1452, is FASII Inhibitor which is potentially for the treatment of acute bacterial skin. AFN-1252 exhibits typical MIC(90) values of ≤0·015 μg/ml against diverse clinical isolates of S. aureus, oral absorption, long elimination half-live and efficacy in animal models. AFN-1252 efficiently blocked daptomycin-induced phospholipid decoy production, even in the case of isolates resistant to AFN-1252, which prevented the inactivation of daptomycin and resulted in sustained bacterial killing. In turn, daptomycin prevented the fatty acid-dependent emergence of AFN-1252-resistant isolates in vitro |
|
| DC74696 |
Bisaramil HCl |
Bisaramil, also known as NK-1556 and RGH-2957, is a calcium channel antagonist and sodium channel antagonist potentially for the treatment of arrhythmia. |
|
| DC74697 |
Ribociclib HCl |
Ribociclib hydrochloride is an potent and orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. Ribociclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. |
|
| DC74698 |
RGB-286638 free base |
RGB-286638 is a multitargeted cyclin-dependent kinase inhibitor. RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. GB-286638 treatment resulted in MM cytotoxicity in vitro associated with inhibition of MM tumor growth and prolonged survival in vivo. RGB-286638 displayed caspase-dependent apoptosis in both wt-p53 and mutant-p53 cells that was closely associated with the downregulation of RNA polymerase II phosphorylation and inhibition of transcription. RGB-286638 triggered p53 accumulation via nucleolar stress and loss of Mdm2, accompanied by induction of p53 DNA-binding activity. |
|
| DC74699 |
Olodanrigan free acid |
Olodanrigan, also known as EMA-401 and PD-126055, is an angiotensin AT2 antagonist potentially for treatment of postherpetic neuralgia (PHN). EMA401 targets angiotensin II type 2 receptors, which may have importance for painful sensitization. EMA401 may alleviate pain and provides relief by blocking the AngII induced potentiation which is thought to be coupled to protein kinase A. |
|
| DC74700 |
Valomaciclovir stearate |
Valomaciclovir stearate (A-174606.0; ABT-606; EPB-348; MIV-606; RP-606) is a DNA polymerase inhibitor potentially for treatment of acute herpes zoster and EB virus infection. Valomaciclovir stearate is an orally available and a prodrug of Valomaciclovir with broad-spectrum antiviral activity against a variety of important herpesviruses, including Epstein-Barr virus, or EBV (the first virus to be directly associated with human cancer), varicella zoster virus, or herpes zoster (cause of shingles), and herpes simplex virus 1 and 2. |
|
| DC74701 |
Doripenem Monohydrate |
Doripenem Monohydrate, also known as S-4661 and Finibax, is a beta-lactam class drug used for bacterial infections with ultra-broad antibiotic spectrum. Doripenem Monohydrate is used commonly for the treatment of complicated intra-abdominal infections and complicated urinary tract infections. |
|
| DC74702 |
Tyramide alkyne |
Tyramide alkyne is an alternative labeling substrate that can be coupled to detection or enrichment moieties via a Copper-catalyzed Azide/Alkyne Cycloaddition (CuAAC) “click” reaction. |
|
| DC74703 |
SCH 23390 HCl |
SCH 23390 is a potent dopamine receptor antagonist (Ki values are 0.2 nM and 0.3 nM at D1 and D5 receptor sub-types, respectively). SCH 23390 is also an agonist at 5-HT1C and 5-HT2C receptors in vitro (Ki values are 6.3 nM and 9.3 nM respectively). |
|
| DC74704 |
MSNBA |
MSNBA is a specific inhibitor of GLUT5 fructose transport in proteoliposomes. |
|
| DC74705 |
MK-0941 mesylate |
MK-0941 mesylate is a glucokinase activator (GKA) potentially for the treatment of type 2 diabetes. MK-0941 led to improvements in glycemic control that were not sustained. MK-0941 was associated with an increased incidence of hypoglycemia and elevations in triglycerides and blood. |
|
| DC74706 |
Trans-crocetin sodium |
Trans-crocetin sodium, also known as Transcrocetinate sodium or Sodium crocetinate, is potentially for the treatment of glioblastoma. Trans-crocetin improves amyloid-β degradation in monocytes from Alzheimer's Disease patients. trans-crocetin inhibit glutamatergic synaptic transmission in rat cortical brain slices. Crocetin inhibits invasiveness of MDA-MB-231 breast cancer cells via downregulation of matrix metalloproteinases. |
|
| DC74707 |
BI-135585 |
BI-135585 is a potent and selective 11β-HSD1 inhibitor. BI 135585 was safe and well tolerated over 14 days and can be dosed once daily. |
|
| DC74708 |
LW3 |
LW3 is a potent antifungal agent. |
|
| DC74709 |
RS5517 |
RS5517 is a specific PDZ1-domain antagonist of NHERF1. |
|
| DC74710 |
Z26395438 |
Z26395438 (compound 1) is a potent Sirtuin-1 inhibitor. |
|
| DC74712 |
CZL55 |
CZL55 is a caspase-1 inhibitor. CZL55 can be used for the research of febrile seizures (FS) |
|
| DC74713 |
Brepocitinib tosylate |
Brepocitinib, also known as PF-06700841, is an inhibitor of JAK1 and TYK2 kinases for potential treatment of systemic lupus erythematosus and plaque psoriasis. PF-06700841 potently inhibits TYK2/JAK2 mediated IL-12/pSTAT4 and IL-23/pSTAT3 (HWB IC50 = 65 and 120 nM, respectively). PF-06700841 improves clinical symptoms of chronic plaque psoriasis by inhibition of proinflammatory cytokines that require TYK2 and Janus kinase 1 for signal transduction. |
|
| DC74714 |
RIG012 |
RIG012 is a potent RIG-I inhibitor. It inhibits IFN-β and ISG hRsad2 expression. |
|
| DC74715 |
Ajmaline |
Ajmaline, also known as Gilurytmal and Ritmos, is a sodium channel blocker used to treat arrhythmia. Ajmaline is also often used to bring out typical findings of ST elevations in patients suspected of having Brugada syndrome. |
|
| DC74716 |
Defactinib HCl |
Defactinib, also known as VS-6063 and PF04554878, is an orally bioavailable, small-molecule focal adhesion kinase (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. Defactinib inhibits FAK, which may prevent the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, thus inhibiting tumor cell migration, proliferation, survival, and tumor angiogenesis. |
|
| DC74717 |
Eg5-IN-1 |
Eg5-IN-1 (compound 6c) is a potent kinesin family motor protein (Eg5) inhibitor |
|
| DC74718 |
WAY-615145 |
WAY-615145 is a glucokinase activator. |
|
| DC74719 |
Bifemelane HCl |
Bifemelane, also known as MCI-2016, is Antidepressant MAO inhibitor used to treat cerebral infarction and Alzheimer's disease. At concentrations of 10 - 30 microM, Bifemelane induced a slow onset and small increase in the [Ca2+]i, while at higher concentrations (100 - 300 microM), it induced a rapid transient increase in the [Ca2+]i during administration and a second large increase was seen during drug washout. |
|
| DC74720 |
Carfecillin Sodium |
Carfecillin Sodium, also known as Carbenicillin Phenyl Sodium and BRL-3475, is the phenyl ester of Carbenicillin that, upon oral administration, is broken down in the intestinal mucosa to the active antibacterial. It is used for urinary tract infections. |
|
| DC74721 |
GPAT-IN-1 |
GPAT-IN-1 is a glycerol-3-phosphate acyltransferase (GPAT) inhibitor |
|
| DC74722 |
MAO-B-IN-19 |
MAO-B-IN-19 is a selective MAO-B inhibitor with an IC50 of 0.67 μM. |
|
| DC74723 |
PNU-282987 free base |
PNU-282987 is a highly selective α7 nAChR agonist (Ki = 26 nM) displaying negligible blockade of α1β1γδ and α3β4 nAChRs (IC50 ≥ 60 μM). PNU-282987 is inactive against a panel of 32 receptors at 1 μM, except 5-HT3 receptors (Ki = 930 nM). |
|
